Tests on adolescents show a vaccine against meningitis B, currently in development, is 90% effective.
The disease mostly affects teenagers, with a fatality rate between 5% to 14%.
The test group developed an immune response against meningitis B, with the only reported side effect being mild pain at the injection site.
Future tests of the vaccine will need to determine the duration of protection.
Read more at The University of Western Australia